LONDON, ONTARIO, Nov 14, 2008 (MARKET WIRE via COMTEX) -- Critical Outcome Technologies Inc. (COT), announced today the Company will meet with several prospective partners for its lead oncology drug candidate COTI-2 at BIO Europe 2008 taking place November 17-19 in Manheim, Germany.

Critical Outcome Technologies Inc. (COTI) has arranged meetings at BIO Europe 2008 with decision makers from several major pharmaceutical organizations including follow-on meetings with previous contacts. The primary objective of the meetings is to present new data on COTI-2 including its novel and potentially first in class mechanism of action and to further explore licensing opportunities regarding its ongoing development. "Several pharmaceutical organizations have shown significant interest in licensing COTI-2 and this new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement," said Mr. Michael Cloutier, CEO of COTI.

COTI has also scheduled several meetings at BIO Europe 2008 to discuss both co-development opportunities related to existing COTI small molecules and also lead discovery collaborations that would be comparable in scope to its ongoing projects with other global pharmaceutical companies. "We remain focused on developing financially viable revenue streams using our proprietary technology, CHEMSAS(R), as we concurrently develop our own novel drug candidates," said Dr. Wayne Danter, President and CSO of COTI.

COTI will be represented at BIO Europe 2008 by Mr. Michael Cloutier, CEO, Dr. Wayne Danter, President and CSO and Mr. Michael Barr, Director of Business Development and Marketing.